 |
PGHAM Transfection Reagent |
|
|
Catalog # 3233 - 0.5 mL $ 145.00
Catalog # 3234 - 1.5 mL $ 336.00
Transfection reagent for PGHAM cells
- Protocols provided for transfection of siRNA and microRNA
- High transfection efficiency
- Kit includes Transfection Enhancer reagent and recommended transfection protocols
- Compatible with transfection in any plate format
- Optimized for PGHAM (hamster Pancreatic Carcinoma Cells)
- Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Developed and manufactured by Altogen Biosystems
Transfection Efficiency:
Reagent exhibits at least 90% transfection
efficiency of siRNA delivery. Transfection efficiency
was determined by fluorescent microscopy and real-time RT-PCR.
Transfection Protocol:
Transfection protocols are provided with
the purchase of the reagent.
|
 |
Transfection Resource |
|
Visit Altogen Biosystems Transfection Resource: RNAi applications (siRNA transfection, microRNA transfection, plasmid DNA transfection), stable and transient DNA transfection, delivery methods, electroporation, microinjection, dendrimer-based, non-viral and virus-mediated gene delivery, liposome and non-liposomal reagents. Transfection of cancer cell lines vs primary cultures. RNA Interference as a research tool for gene expression studies, gene silencing in neuronal cells, RNAi therapeutics and In Vivo Transfection Reagents from Altogen Biosystems.
 |
PGHAM (hamster Pancreatic Carcinoma Cells) |
|
PGHAM-1 cell line was derived from an N-nitrosobis(2-oxopropyl)amine (BOP)-induced pancreatic tumor in a Syrian hamster. The tumors were minced and subcutaneously transplanted with a trocar into the interscapular area of untreated 5-week-old hamsters. The recipient hamsters were killed at 6–8 weeks after transplantation, and a portion of the tumor tissue was serially transplanted. After subcutaneous transplantation 8 times, the tumor was extracted under germ-free conditions, Cells that had been maintained in culture for 60 passages and had become established as a cell line were named PGHAM-1 The tumor showed a striking similarity to human pancreatic ductal adenocarcinoma and had a moderate to well-differentiated histology. PGHAM-1 contains a K-ras point mutation at codon 12, one of the most frequent types of K-ras mutation in human pancreatic cancers. Researchers have frequently used PGHAM-1 in experiments because of their cells’ rapid growth and a high rate of metastasis.
 |
Transfection Resource |
|
siRNA Transfection || Transfection Methods || Stable Transfection || RNAi || siRNA Library Screening || RNAi Therapeutics || Cell Transfection || In Vivo Transfection Reagents || Cell Line Specific Transfection Reagents
 |
Featured Products |
|
In Vivo Transfection Reagents || Fibroblast Cells Transfection Reagent || Astrocyte Cells Transfection Reagent || HEK-293 Transfection Reagent || MEF Transfection Reagent || HepG2 Transfection Reagent || CHO Reagent || MDA-MB Transfection Reagent || Cos7 Transfection Reagent || A549 Transfection Reagent || NIH3T3 Reagent || HUVEC Transfection Reagent || LNCaP Transfection Reagent || MCF-7 Reagent || PC-12 Reagent
 |
Altogen Research Services |
|
Altogen Custom Services provide specialized biotechnology and pharmaceutical services, including - generation of stable cell lines, RNA Interference (RNAi) services, assay development, screening and transfection services. Generation of stably-expressing cancer cell lines and primary cells can be very expensive and time-consuming. Altogen Services offers generation of stable cell lines by transforming the cell line of choice to stably express gene of interest or shRNA-encoding construct. Cloning and shRNA expression services are available.
|